NASDAQ: GELSGelteq Ltd Stock
$0.65+0.00 (+0%)
Updated Apr 30, 2026
GELS Price
$0.65
Fair Value Price
-$0.30
Market Cap
$6.91M
52 Week Low
$0.62
52 Week High
$3.51
P/E
-1.37x
P/B
0.67x
P/S
149.78x
PEG
N/A
Dividend Yield
N/A
Revenue
$108.26k
Earnings
-$4.37M
Gross Margin
30.3%
Operating Margin
-2,834.31%
Profit Margin
-4,011.9%
Debt to Equity
0.36
Operating Cash Flow
-$4M
Beta
1.88
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
GELS Overview
Gelteq Limited focuses on developing and commercializing a gel-based delivery system for humans and animals. It offers white label gel-based delivery solutions for prescription drugs, over-the-counter products, nutraceuticals and sports, pet care, and other products. The company was incorporated in 2017 and is headquartered in Caulfield, Australia.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GELS's potential to beat the market
- GELS doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
A
GELS
RankedUnranked of 52
RankedUnranked of 52
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $12.87 | A | |
| $36.78 | A | |
| $16.68 | A |
Be the first to know about important GELS news, forecast changes, insider trades & much more!
GELS News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GELS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GELS ($0.65) is overvalued by 316.62% relative to our estimate of its Fair Value price of -$0.30 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GELS ($0.65) is not significantly undervalued (316.62%) relative to our estimate of its Fair Value price of -$0.30 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GELS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GELS due diligence checks available for Premium users.
Valuation
GELS fair value
Fair Value of GELS stock based on Discounted Cash Flow (DCF)
Price
$0.65
Fair Value
-$0.30
Undervalued by
318.29%
GELS ($0.65) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GELS ($0.65) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GELS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GELS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.37x
Industry
-178.23x
Market
18.99x
GELS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.67x
Industry
1.63x
GELS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GELS's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
GELS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
GELS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$14.1M
Liabilities
$3.7M
Debt to equity
0.36
GELS's short-term liabilities ($3.68M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GELS's short-term assets ($984.75k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GELS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GELS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
GELS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GELS vs Pharmaceutical Stocks
Gelteq Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.